Expression of Programmed Cell Death-1 (PD-1) and Its Ligand (PD-L1) in Breast Cancers and Its Association with Clinicopathological Parameters: A Study from North India

Introduction Cancer immunotherapy targeting the programmed cell death ligand 1 (PD-L1) and programmed cell death-1 (PD-1) axis has revolutionized cancer therapy. PD-L1 also serves as a predictive marker for such therapy. To assess the potential of such therapy in any cancer, the positivity of PD-1 a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anoushika Mehan, Michael Leonard Anthony, Pranoy Paul, Anjum Syed, Nilotpal Chowdhury, Shalinee Rao, Nuzhat Hussain, Bina Ravi
Formato:	article
Lenguaje:	EN
Publicado:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2021
Materias:	programmed cell death 1 ligand 1 programmed cell death 1 receptor breast carcinoma Medicine R
Acceso en línea:	https://doaj.org/article/3e7680abb3dd43d2ad4124ebd1b85cd7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3e7680abb3dd43d2ad4124ebd1b85cd7
record_format	dspace
spelling	oai:doaj.org-article:3e7680abb3dd43d2ad4124ebd1b85cd72021-11-10T23:57:22ZExpression of Programmed Cell Death-1 (PD-1) and Its Ligand (PD-L1) in Breast Cancers and Its Association with Clinicopathological Parameters: A Study from North India0974-27270974-782610.1055/s-0041-1736522https://doaj.org/article/3e7680abb3dd43d2ad4124ebd1b85cd72021-11-01T00:00:00Zhttp://www.thieme-connect.de/DOI/DOI?10.1055/s-0041-1736522https://doaj.org/toc/0974-2727https://doaj.org/toc/0974-7826Introduction Cancer immunotherapy targeting the programmed cell death ligand 1 (PD-L1) and programmed cell death-1 (PD-1) axis has revolutionized cancer therapy. PD-L1 also serves as a predictive marker for such therapy. To assess the potential of such therapy in any cancer, the positivity of PD-1 and PD-L1 in such cancers needs to be assessed. However, such studies for breast cancer are lacking in South Asia. We aimed to estimate the positivity of PD-L1 and PD-1 receptors in breast cancer and its various clinicopathological groups in our patient population. Materials and Methods We studied the immunoexpression of PD-1 and PD-L1 in 103 histologically proven invasive carcinoma breast cases from October 2018 to April 2019. The percent positivity of PD-1 and PD-L1 with 95% confidence intervals (CI) was estimated for all the cases as well as groups defined by stage, grade, molecular subtype, hormone receptor status, Ki-67, and age. Results PD-1 positivity was seen in 72 (69.9%) cases (95% CI: 60.1–78.6). PD-L1 immunoexpression was seen in 61 (59.2%) cases (95% CI: 49.1–68.8) in immune cells and in 39 (37.9%) cases (95% CI: 28.5–50.0) in tumor cells. No significant association was found between PD-1, PD-L1 and age, overall clinical stage, grade, size, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67. Moderate-to-high PD-1 and PD-L1 immunopositivity was seen in all subtypes of breast cancer. Conclusion PD-1 and PD-L1 is expressed in all subgroups of breast carcinoma. Patients in all such groups are amenable to immunotherapy, provided they are found suitable otherwise.Anoushika MehanMichael Leonard AnthonyPranoy PaulAnjum SyedNilotpal ChowdhuryShalinee RaoNuzhat HussainBina RaviThieme Medical and Scientific Publishers Pvt. Ltd.articleprogrammed cell death 1 ligand 1programmed cell death 1 receptorbreast carcinomaMedicineRENJournal of Laboratory Physicians (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	programmed cell death 1 ligand 1 programmed cell death 1 receptor breast carcinoma Medicine R
spellingShingle	programmed cell death 1 ligand 1 programmed cell death 1 receptor breast carcinoma Medicine R Anoushika Mehan Michael Leonard Anthony Pranoy Paul Anjum Syed Nilotpal Chowdhury Shalinee Rao Nuzhat Hussain Bina Ravi Expression of Programmed Cell Death-1 (PD-1) and Its Ligand (PD-L1) in Breast Cancers and Its Association with Clinicopathological Parameters: A Study from North India
description	Introduction Cancer immunotherapy targeting the programmed cell death ligand 1 (PD-L1) and programmed cell death-1 (PD-1) axis has revolutionized cancer therapy. PD-L1 also serves as a predictive marker for such therapy. To assess the potential of such therapy in any cancer, the positivity of PD-1 and PD-L1 in such cancers needs to be assessed. However, such studies for breast cancer are lacking in South Asia. We aimed to estimate the positivity of PD-L1 and PD-1 receptors in breast cancer and its various clinicopathological groups in our patient population. Materials and Methods We studied the immunoexpression of PD-1 and PD-L1 in 103 histologically proven invasive carcinoma breast cases from October 2018 to April 2019. The percent positivity of PD-1 and PD-L1 with 95% confidence intervals (CI) was estimated for all the cases as well as groups defined by stage, grade, molecular subtype, hormone receptor status, Ki-67, and age. Results PD-1 positivity was seen in 72 (69.9%) cases (95% CI: 60.1–78.6). PD-L1 immunoexpression was seen in 61 (59.2%) cases (95% CI: 49.1–68.8) in immune cells and in 39 (37.9%) cases (95% CI: 28.5–50.0) in tumor cells. No significant association was found between PD-1, PD-L1 and age, overall clinical stage, grade, size, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67. Moderate-to-high PD-1 and PD-L1 immunopositivity was seen in all subtypes of breast cancer. Conclusion PD-1 and PD-L1 is expressed in all subgroups of breast carcinoma. Patients in all such groups are amenable to immunotherapy, provided they are found suitable otherwise.
format	article
author	Anoushika Mehan Michael Leonard Anthony Pranoy Paul Anjum Syed Nilotpal Chowdhury Shalinee Rao Nuzhat Hussain Bina Ravi
author_facet	Anoushika Mehan Michael Leonard Anthony Pranoy Paul Anjum Syed Nilotpal Chowdhury Shalinee Rao Nuzhat Hussain Bina Ravi
author_sort	Anoushika Mehan
title	Expression of Programmed Cell Death-1 (PD-1) and Its Ligand (PD-L1) in Breast Cancers and Its Association with Clinicopathological Parameters: A Study from North India
title_short	Expression of Programmed Cell Death-1 (PD-1) and Its Ligand (PD-L1) in Breast Cancers and Its Association with Clinicopathological Parameters: A Study from North India
title_full	Expression of Programmed Cell Death-1 (PD-1) and Its Ligand (PD-L1) in Breast Cancers and Its Association with Clinicopathological Parameters: A Study from North India
title_fullStr	Expression of Programmed Cell Death-1 (PD-1) and Its Ligand (PD-L1) in Breast Cancers and Its Association with Clinicopathological Parameters: A Study from North India
title_full_unstemmed	Expression of Programmed Cell Death-1 (PD-1) and Its Ligand (PD-L1) in Breast Cancers and Its Association with Clinicopathological Parameters: A Study from North India
title_sort	expression of programmed cell death-1 (pd-1) and its ligand (pd-l1) in breast cancers and its association with clinicopathological parameters: a study from north india
publisher	Thieme Medical and Scientific Publishers Pvt. Ltd.
publishDate	2021
url	https://doaj.org/article/3e7680abb3dd43d2ad4124ebd1b85cd7
work_keys_str_mv	AT anoushikamehan expressionofprogrammedcelldeath1pd1anditsligandpdl1inbreastcancersanditsassociationwithclinicopathologicalparametersastudyfromnorthindia AT michaelleonardanthony expressionofprogrammedcelldeath1pd1anditsligandpdl1inbreastcancersanditsassociationwithclinicopathologicalparametersastudyfromnorthindia AT pranoypaul expressionofprogrammedcelldeath1pd1anditsligandpdl1inbreastcancersanditsassociationwithclinicopathologicalparametersastudyfromnorthindia AT anjumsyed expressionofprogrammedcelldeath1pd1anditsligandpdl1inbreastcancersanditsassociationwithclinicopathologicalparametersastudyfromnorthindia AT nilotpalchowdhury expressionofprogrammedcelldeath1pd1anditsligandpdl1inbreastcancersanditsassociationwithclinicopathologicalparametersastudyfromnorthindia AT shalineerao expressionofprogrammedcelldeath1pd1anditsligandpdl1inbreastcancersanditsassociationwithclinicopathologicalparametersastudyfromnorthindia AT nuzhathussain expressionofprogrammedcelldeath1pd1anditsligandpdl1inbreastcancersanditsassociationwithclinicopathologicalparametersastudyfromnorthindia AT binaravi expressionofprogrammedcelldeath1pd1anditsligandpdl1inbreastcancersanditsassociationwithclinicopathologicalparametersastudyfromnorthindia
_version_	1718439663349268480

Expression of Programmed Cell Death-1 (PD-1) and Its Ligand (PD-L1) in Breast Cancers and Its Association with Clinicopathological Parameters: A Study from North India

Ejemplares similares